

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

3-762

Examiner: (not yet assigned)

Art Unit: 3762

Katzman et al.

Serial No.:

10/549,488

Filed:

July 31, 2006

Entitled:

Modafinil-Based Neurorehabilitaion

Of Impaired Neurological Function Associated

With Brain Injury

Attorney Docket No.: NEU-102.1P US

Mail Stop AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith are: [X] an Information Disclosure Statement (IDS) under 37 CFR §§ 1.56, 1.97 and 1.98; [X] Form PTO-1449 Information Disclosure Statement; [X] photocopies of the disclosed documents, to be filed in the above-identified patent application; and [X] a return receipt post card.

### **PAYMENT OF FEES**

[]	A check in the amount of \$ (check no.	) in payment of the fee for submission of an
	information disclosure statement transmitted h	erewith.

The Commissioner is hereby authorized to charge payment of any additional fees required under [X] 37 CFR §§ 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0268. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

Thomas R. Berka, Ph.D., Reg. No. 39,606

Leon R. Yankwich, Reg. No. 30,237

Attorneys for Applicants

YANKWICH & ASSOCIATES, P.C.

201 Broadway

Cambridge, Massachusetts 02139

telephone: (617) 374-3700

telefax: (617) 374-0055



# **CERTIFICATE OF MAILING**

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

03/21/2007

Date

Meghan F. M. Fadden



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit: 3762

Examiner: (not yet assigned)

Katzman et al.

Serial No.:

10/549,488

Filed:

July 31, 2006

Entitled:

Modafinil-Based Neurorehabilitation Of

Impaired Neurological Function

Associated With Brain Injury

Attorney Docket No.: NEU-102.1P US

#### Mail Stop Amendment

Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450

# INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A modified Form PTO-1449 listing the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents. This Statement is being submitted before the first Office Action on the merits pursuant to 37 C.F.R. § 1.97(b)(3). Accordingly, no fee is required with this submission.

#### **United States Patents**

4,927,855, issued May 22, 1990, Lafon, L.

5,612,379, issued March 18, 1997, Laurent, P.

6,463,328, issued October 8, 2002, John, M.

6,489,363, issued December 3, 2002, Jacobs et al.

RE37,516 E, revised January 15, 2002, Grebow et al.

US 2006/0135621, published June 22, 2006, Neckebrock et al.

U.S. Serial No. 10/549,488 (Atty. Docket No. NEU-102.1P US)

### **Other Documents**

Bastuji et al., Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 12: 695-700 (1988)

Donovan et al., Ther. Drug Monit., 25(2): 197-202 (2003)

Duteil et al., Eur. J. Pharmacol., 180: 49-58 (1990)

Physicians Desk Reference, 58th ed., (Thomson, Montvale, New Jersey, 2004), p. 1160-1163

Rappaport et al., Arch. Phys. Med. Rehabil., 63: 118-123 (1982)

Saletu et al., Int. J. Clin. Pharm. Res., 9: 183-195 (1989)

Wisor et al., J. Neuroscience, 21(5): 1787-1794 (2001)

Applicants do not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicants respectfully request that the documents submitted herein be considered and made of record in this application, and also printed on any patent issuing from the above-identified application.

Respectfully submitted,

Thomas R. Berka, Ph.D. Reg. No. 39,606

Thomas R. Buka

Leon R. Yankwich, Reg. No. 30,237

Attorneys for Applicants

YANKWICH & ASSOCIATES, P.C.

201 Broadway

Cambridge, Massachusetts 02139

telephone: (617) 374-3700 telefax: (617) 374-0055

U.S. Serial No. 10/549,488 (Atty. Docket No. NEU-102.1P US)

Certificate	of	Ma	ili	ng
-------------	----	----	-----	----

The undersigned hereby certifies that this correspondence and accompanying documents are being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

03/21/2007

date

Modified FORM PTO-1449  MAR 2 3 2007	ATTY. DOCKET NO. NEU-102.1P US	<b>SERIAL NO.</b> 10/549,488
LIST OF PATENTS AND POPULATION S FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Katzman et al.	
(Use several sheets if necessary)	FILING DATE July 31, 2006	<b>GROUP</b> 3762

REFERENCE DESIGNATION

**U.S. PATENT DOCUMENTS** 

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,927,855	05/22/1990	Lafon, L.			
	AB	5,612,379	03/18/1997	Laurent, P.			
	AC	6,463,328	10/08/2002	John, M.			
	AD	6,489,363	12/03/2002	Jacobs et al.		244-1-2	
	AE	RE37,516 E	01/15/2002	Grebow et al.			
	AF	US 2006/0135621	07/22/2006	Neckebrock et al.			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

7	(including reacher) Field, Date, Fortherner ages, Etc.)
AG	Bastuji et al., Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 12: 695-700 (1988)
AH	Donovan et al., Ther. Drug Monit., 25(2): 197-202 (2003)
AI	Duteil et al., Eur. J. Pharmacol., 180: 49-58 (1990)
AJ	Physician's Desk Reference, 58th ed., (Thomson, Montvale, New Jersey, 2004), p. 1160-1163
AK	Rappaport et al., Arch. Phys. Med. Rehabil., 63: 118-123 (1982)
AL	Saletu et al., Int. J. Clin. Pharm. Res., 9: 183-195 (1989)
AM	Wisor et al., J. Neuroscience, 21(5): 1787-1794 (2001)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ahaat	1	~ C	1
sheet	I	of	1